Showing results (121-130 of 203) with videos related to

Sort By:
Pageof 21
Cancer Chemotherapy and Pharmacology|October 1, 2013
Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I studyRachel C Jankowitz, Jame Abraham, Antoinette R Tan, et al.
The Lancet. Oncology|October 3, 2024
The tyranny of non-inferiority trialsIan F Tannock, Marc Buyse, Mickael De Backer, et al.
BMJ Open|March 15, 2013
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trialsSilvy Laporte, Pierre Squifflet, Noémie Baroux, et al.
Ophthalmology|February 8, 2023
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular DegenerationTimothy L Jackson, Jason Slakter, Marc Buyse, et al.
JAMA|May 6, 2010
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis, Xavier Paoletti, Koji Oba, et al.
Eclinicalmedicine|September 11, 2025
Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney diseaseRod S Taylor, Hiddo J L Heerspink, Marc Buyse, et al.
The Lancet. Oncology|February 3, 2019
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysisEverardo D Saad, Pierre Squifflet, Tomasz Burzykowski, et al.
Advances in Radiation Oncology|December 16, 2024
Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary AnalysisCarryn Anderson, Samuel Salvaggio, Mickaël De Backer, et al.
Clinical Trials (London, England)|July 24, 2019
Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoringLaura Trotta, Yuusuke Kabeya, Marc Buyse, et al.
International Journal of Cancer|August 25, 2006
Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patientsChristine Desmedt, Frank El Ouriaghli, Virginie Durbecq, et al.
Pageof 21